Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04475393Not ApplicableActive Not Recruiting

Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure

Role: lead

NCT05474092Recruiting

Aeson TAH System - Post-Market Clinical Follow-up Study

Role: lead

NCT02962973Not ApplicableSuspended

European Clinical Evaluation of the Carmat Total Artificial Heart

Role: lead

NCT04117295Not ApplicableSuspended

Carmat TAH Early Feasibility Study

Role: lead

All 4 trials loaded